POAI News and Press, Predictive Oncology Inc. From 04/04/23

EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...

Predictive Oncology (NASDAQ: POAI) , a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to ...

EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of&#x...

2023-03-22 19:05:07 ET Predictive Oncology, Inc. (POAI) Q4 2022 Earnings Conference Call March 22, 2023 12:00 PM ET Company Participants Theresa Ferguson - Senior Director of Marketing Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers ...

Predictive Oncology’s (NASDAQ: POAI) chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, joined Proactive’s Natalie Stoberman to discuss their partnership for new cancer drug development. According to the announcement, ...

2023-03-21 17:26:45 ET Predictive Oncology press release ( NASDAQ: POAI ): FY  GAAP EPS of -$0.35. Revenue of $1.51M (+6.3% Y/Y). For further details see: Predictive Oncology GAAP EPS of -$0.35, revenue of $1.51M

EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (...

--News Direct-- Predictive Oncology chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, join Proactive's Natalie Stoberman to discuss their new partnership for new cancer drug development. The collaboration will utilize Predictive ...

Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, i...

2023-03-17 07:29:21 ET Predictive Oncology ( NASDAQ: POAI ) is collaborating with Cancer Research Horizons (CRH) to develop cancer drugs. CRH is the innovation arm of Cancer Research UK –  one of the world's largest charitable funders of cancer research,&#...